241 related articles for article (PubMed ID: 10792287)
1. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
3. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
5. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.
Cull G; Durrant L; Stainer C; Haynes A; Russell N
Br J Haematol; 1999 Dec; 107(3):648-55. PubMed ID: 10583271
[TBL] [Abstract][Full Text] [Related]
6. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
7. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
[TBL] [Abstract][Full Text] [Related]
8. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL
Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473
[TBL] [Abstract][Full Text] [Related]
9. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
10. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
Osterborg A; Henriksson L; Mellstedt H
Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
[TBL] [Abstract][Full Text] [Related]
11. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
[TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma.
Lim SH; Bailey-Wood R
Int J Cancer; 1999 Oct; 83(2):215-22. PubMed ID: 10471530
[TBL] [Abstract][Full Text] [Related]
14. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
Ratta M; Curti A; Fogli M; Pantucci M; Viscomi G; Tazzari P; Fagnoni F; Vescovini R; Sansoni P; Tura S; Lemoli RM
Exp Hematol; 2000 Aug; 28(8):931-40. PubMed ID: 10989194
[TBL] [Abstract][Full Text] [Related]
15. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
[TBL] [Abstract][Full Text] [Related]
16. [In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine].
Zhang M; Yin XR; Luo YY; Lin X; Wang MC; He PC; Li J; Guo GL; Cai RH; Liu YL
Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):593-7. PubMed ID: 16532967
[TBL] [Abstract][Full Text] [Related]
17. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
[TBL] [Abstract][Full Text] [Related]
18. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
19. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Yi Q; Desikan R; Barlogie B; Munshi N
Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
[TBL] [Abstract][Full Text] [Related]
20. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]